Get the Stockscreener App
31.31
1.23%
0.38
Pre-market:
30.01
-1.30
-4.15%
Quince Therapeutics Inc stock is traded at $31.31, with a volume of 13,633.
It is up +1.23% in the last 24 hours and up +75.36% over the past month.
Quince Therapeutics Inc is a late-stage biotechnology company dedicated to unlocking the power of a patient's own biology for the treatment of rare diseases. Its proprietary AIDE technology is an inventive drug/device combination platform that uses an automated process to encapsulate a drug into a patient's own red blood cells. Its Phase 3 asset, eDSP, leverages the AIDE technology to encapsulate DSP into a patient's own red blood cells, and is targeted to treat a rare pediatric neurodegenerative disease, A-T.
See More
Previous Close:
$30.93
Open:
$31.9
24h Volume:
13,633
Relative Volume:
0.38
Market Cap:
$31.84M
Revenue:
-
Net Income/Loss:
$-33.04M
P/E Ratio:
-3.4398
EPS:
-9.1023
Net Cash Flow:
$-39.66M
1W Performance:
-9.43%
1M Performance:
+75.36%
6M Performance:
+13.03%
1Y Performance:
-90.22%
1-Day Range:
$31.31
$32.01
1-Week Range:
$30.93
$35.15
52-Week Range:
$15.10
$909.98
Quince Therapeutics Inc Stock (QNCX) Company Profile
Name
Quince Therapeutics Inc
Sector
Industry
Phone
415-910-5717
Address
611 GATEWAY BLVD., SUITE 273, SOUTH SAN FRANCISCO
Compare QNCX vs VRTX, REGN, ARGX, MRNA, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
QNCX
Quince Therapeutics Inc
|
31.31 | 32.66M | 0 | -33.04M | -39.66M | -9.1023 |
VRTX
Vertex Pharmaceuticals Inc
|
547.29 | 136.93B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
814.79 | 85.11B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
1,047.10 | 64.95B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
149.66 | 53.23B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
215.44 | 45.38B | 742.00K | -1.37B | -1.07B | -7.0731 |
Quince Therapeutics Inc Stock (QNCX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-30-26 | Downgrade | Citizens JMP | Mkt Outperform → Mkt Perform |
| Aug-05-25 | Initiated | Citizens JMP | Mkt Outperform |
| Mar-24-25 | Initiated | Oppenheimer | Outperform |
Quince Therapeutics Inc Stock (QNCX) Latest News
Quince Therapeutics forms Scientific Advisory Board to advance LAM-001 - scanx.trade
Quince (QNCX) Results at a Glance: The Available Earnings Metric Delivers a Beat; Market Move: Shares Finish 7.12% Lower in the Available RecordEarnings Seasonality - vinanet.vn
Balyasny Asset Management L.P. Initiates New Position in Quince Therapeutics Inc (QNCX) - GuruFocus
Craig-Hallum Initiates Quince Therapeutics(QNCX.US) With Buy Rating, Announces Target Price $68 - Moomoo
Quince (QNCX) Chart: Slides 0.90% to $34.26 at the Close; Price Setup: Price Remains Between $32.55 Support and $35.97 Resistance in the Available RecordSentiment Divergence - vinanet.vn
Craig-Hallum Initiates Coverage on Quince Therapeutics (QNCX) wi - GuruFocus
symbol__ Stock Quote Price and Forecast - CNN
LifeSci Capital Maintains Quince Therapeutics(QNCX.US) With Buy Rating, Cuts Target Price to $98 - Moomoo
Quince Therapeutics stock rating reiterated by Cantor Fitzgerald - Investing.com
QNCX Reiterated by Cantor Fitzgerald -- Price Target Maintained at $70 - GuruFocus
Quince Plans Shareholder Vote on Major Stock Issuance - The Globe and Mail
Form 8K Quince Therapeutics Inc For: 17 August By Investing.com - Investing.com Nigeria
Quince Therapeutics Closes Orphai Acquisition With $115M PIPE Financing - Minichart
Quince Therapeutics plans special meeting to vote on share issuance and potential change of control - Investing.com
Quince Therapeutics to seek shareholder OK for Series C conversion, adding ~11M shares and reclassifying $6.3M warrants - TradingView
Ikarian Capital discloses 9.0% Quince Therapeutics (QNCX) ownership in Schedule 13G - Stock Titan
Nantahala Capital (QNCX) reports 0% stake in Quince Therapeutics in latest 13G/A - Stock Titan
Quince Therapeutics (QNCX) Jumps 5% to $34.04 as Bulls Target $35.74 ResistanceBlue Chip Entry Points - vinanet.vn
Quince Therapeutics (QNCX) books $39.6M loss but lifts cash to $116M - Stock Titan
Quince Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
Quince Therapeutics, Inc. (NASDAQ: QNCX) Stock Price, News & Analysis - Kalkine
Quince Therapeutics Releases Q2 2026 Financial Results - AlphaStreet
Cormorant Asset Management (QNCX) reports 9.99% Quince Therapeutics stake via convertibles - Stock Titan
Quince Therapeutics Q2 EPS of $(12.31) beats $(26.32) estimate - scanx.trade
Quince Therapeutics, Inc. reports results for the quarter ended June 30Earnings Summary - TradingView
Form 8K Quince Therapeutics Inc For: 14 August By Investing.com - Investing.com Nigeria
Quince Therapeutics Reports Second Quarter 2026 Financial Results And Corporate Update - TradingView
Quince Reports $75.5 Million Second Quarter Net Loss After Orphai Deal - Quiver Quantitative
QNCX: Orphai acquisition, $115M financing, and LAM-001 trial progress define a pivotal Q2 2026 - TradingView
Quince Therapeutics reports $75.5M Q2 net loss, $116M cash as of June 30, 2026 - TradingView
Quince Therapeutics Q2 net loss widens on acquisition charges - TradingView
Quince Therapeutics Reports Second Quarter 2026 Financial Results and Corporate Update - The Manila Times
Quince Adds Inhaled Rapamycin Program for Pulmonary Diseases - Stock Titan
Quince Therapeutics (QNCX): Balyasny group discloses 9.99% beneficial stake cap - Stock Titan
Quince Therapeutics (QNCX) Pushes Higher, Up 3.68% as Shares Test Key Resistance at $34.03Iron Condor Alert - Vinanet
Quince Therapeutics, Inc. expected to post a loss of $17.88 a shareEarnings Preview - TradingView
Quince Therapeutics (QNCX) updates S-3 shelf with legal opinion and $498K in costs - Stock Titan
Quince Therapeutics (QNCX) sees Squadron group report 5.6% ownership stake - Stock Titan
QNCX Q2'26 Earnings: revenue estimate is 0 USD - TradingView
Quince Therapeutics (QNCX) Climbs 6.73% to $24.96, Testing Key Resistance ZoneCall Spread Alert - vinanet.vn
Quince Therapeutics Inc (QNCX) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Quince Therapeutics Announces Leadership Transition to Orphai Team - The Globe and Mail
Form S-3 Quince Therapeutics For: 31 July By Investing.com - Investing.com Canada
Quince Therapeutics (QNCX) files resale for 15.5M shares tied to Orphai deal - Stock Titan
Quince Therapeutics Q1 2026 Earnings: Massive EPS Surprise Driven by Non-Operating GainsEarnings Forecast Report - vinanet.vn
QNCX Initiated by Oppenheimer -- Rating Set to Outperform with $82 Target - GuruFocus
Oppenheimer Initiates Quince Therapeutics(QNCX.US) With Buy Rating, Announces Target Price $82 - Moomoo
Quince Therapeutics Inc (QNCX) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Quince Therapeutics Inc (QNCX) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
TradingKey - TradingKey
Quince Therapeutics Inc (QNCX) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Quince Therapeutics Inc Stock (QNCX) Financials Data
Revenue
Net Income
Cash Flow
EPS
Quince Therapeutics Inc Stock (QNCX) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Benatti Luca | Director |
Dec 26 '25 |
Sale |
3.47 |
50,000 |
173,500 |
39,179 |
| Hannah Brendan | CBO, COO & CCO |
Dec 05 '25 |
Option Exercise |
0.91 |
27,551 |
25,012 |
361,827 |
0.40%
0.43%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):